Inclisiran: First Approval.
Lamb YN.
Drugs. 2021 Feb;81(3):389-395. doi: 10.1007/s40265-021-01473-6.
Research advances in current drugs targeting hyperlipidemia (Review).
Zhao H, Wang Y, Li Y, Cheng R, Chen W.
Mol Med Rep. 2025 Oct;32(4):258. doi: 10.3892/mmr.2025.13623. Epub 2025 Jul 19.
Tafolecimab: First Approval.
Keam SJ.
Drugs. 2023 Nov;83(16):1545-1549. doi: 10.1007/s40265-023-01952-y.
Recaticimab: First Approval.
Lamb YN.
Drugs. 2025 Aug;85(8):1067-1072. doi: 10.1007/s40265-025-02199-5. Epub 2025 Jun 23.
Ezetimibe.
Sizar O, Nassereddin A, Talati R.
2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Addressing the underdiagnosis of familial hypercholesterolemia: A mixed methods study exploring the knowledge and practice behaviors of cardiology healthcare providers.
Kalia I, Shope R, Reilly M, Schwartz L.
J Clin Transl Sci. 2023 Apr 5;7(1):e92. doi: 10.1017/cts.2023.519. eCollection 2023.
Familial Hypercholesterolemia Prevalence Among Ethnicities-Systematic Review and Meta-Analysis.
Toft-Nielsen F, Emanuelsson F, Benn M.
Front Genet. 2022 Feb 3;13:840797. doi: 10.3389/fgene.2022.840797. eCollection 2022.
Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties.
Masana Marín L, Plana Gil N.
Clin Investig Arterioscler. 2021 May;33 Suppl 1:53-57. doi: 10.1016/j.arteri.2021.02.012.
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-Shiba M, Blom DJ, Raal FJ, Cuchel M; Homozygous Familial Hypercholesterolaemia International Clinical Collaborators.
Lancet. 2022 Feb 19;399(10326):719-728. doi: 10.1016/S0140-6736(21)02001-8. Epub 2022 Jan 28.
Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia.
Pedro-Botet J, Climent E, Gabarró N, Millán J.
Clin Investig Arterioscler. 2021 May;33 Suppl 2:43-49. doi: 10.1016/j.arteri.2020.12.013.
